| Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma TS Mok, YL Wu, S Thongprasert, CH Yang, DT Chu, N Saijo, ... New England Journal of Medicine 361 (10), 947-957, 2009 | 10059 | 2009 |
| Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma TS Mok, YL Wu, S Thongprasert, CH Yang, DT Chu, N Saijo, ... New England Journal of Medicine 361 (10), 947-957, 2009 | 10059 | 2009 |
| Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer J Ledermann, P Harter, C Gourley, M Friedlander, I Vergote, G Rustin, ... New England Journal of Medicine 366 (15), 1382-1392, 2012 | 2091 | 2012 |
| Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial ES Kim, V Hirsh, T Mok, MA Socinski, R Gervais, YL Wu, LY Li, ... The Lancet 372 (9652), 1809-1818, 2008 | 1737 | 2008 |
| Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non–small-cell lung cancer FR Hirsch, M Varella-Garcia, PA Bunn Jr, WA Franklin, R Dziadziuszko, ... Journal of clinical oncology 24 (31), 5034-5042, 2006 | 913 | 2006 |
| Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial JY Douillard, FA Shepherd, V Hirsh, T Mok, MA Socinski, R Gervais, ... J clin Oncol 28 (5), 744-752, 2010 | 624 | 2010 |
| Gut bifidobacteria populations in human health and aging S Arboleya, C Watkins, C Stanton, RP Ross Frontiers in microbiology 7, 212275, 2016 | 597 | 2016 |
| Evolution of gut microbiota composition from birth to 24 weeks in the INFANTMET Cohort CJ Hill, DB Lynch, K Murphy, M Ulaszewska, IB Jeffery, CA O’Shea, ... Microbiome 5, 1-18, 2017 | 568 | 2017 |
| Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study S Kudoh, H Kato, Y Nishiwaki, M Fukuoka, K Nakata, Y Ichinose, ... American journal of respiratory and critical care medicine 177 (12), 1348-1357, 2008 | 488 | 2008 |
| Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: subset analysis from the ISEL study A Chang, P Parikh, S Thongprasert, EH Tan, RP Perng, D Ganzon, ... Journal of thoracic oncology 1 (8), 847-855, 2006 | 284 | 2006 |
| Dietary fat, the gut microbiota, and metabolic health–A systematic review conducted within the MyNewGut project M Wolters, J Ahrens, M Romaní-Pérez, C Watkins, Y Sanz, ... Clinical nutrition 38 (6), 2504-2520, 2019 | 246 | 2019 |
| Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first-or second-line treatment of patients with metastatic triple-negative breast cancer RA Dent, GJ Lindeman, M Clemons, H Wildiers, A Chan, NJ McCarthy, ... Breast cancer research 15, 1-8, 2013 | 221 | 2013 |
| Perinatal factors affect the gut microbiota up to four years after birth F Fouhy, C Watkins, CJ Hill, CA O’Shea, B Nagle, EM Dempsey, ... Nature communications 10 (1), 1517, 2019 | 218 | 2019 |
| Phase III, randomized, open-label, first-line study of gefitinib vs carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer (IPASS) T Mok ESMO abstr, 2008, 2008 | 208 | 2008 |
| Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor–positive metastatic breast cancer M Cristofanilli, V Valero, A Mangalik, M Royce, I Rabinowitz, FP Arena, ... Clinical Cancer Research 16 (6), 1904-1914, 2010 | 200 | 2010 |
| Effect of convalescent plasma on organ support–free days in critically ill patients with COVID-19: a randomized clinical trial H Abdelhady, M Abdelrazik, Z Abdi, D Abdo, A Abdulle, L Abel, ... Jama 326 (17), 1690-1702, 2021 | 189 | 2021 |
| Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients (pts) with EGFR inhibitor–resistant non-small cell lung cancer (NSCLC). PA Janne, SS Ramalingam, JCH Yang, MJ Ahn, DW Kim, SW Kim, ... Journal of Clinical Oncology 32 (15_suppl), 8009-8009, 2014 | 187 | 2014 |
| Biomarker analyses from a phase III, randomized, open-label, first-line study of gefitinib (G) versus carboplatin/paclitaxel (C/P) in clinically selected patients (pts) with … M Fukuoka, Y Wu, S Thongprasert, C Yang, D Chu, N Saijo, C Watkins, ... Journal of Clinical Oncology 27 (15_suppl), 8006-8006, 2009 | 119 | 2009 |
| Epidermal growth factor receptor immunohistochemistry: Comparison of antibodies and cutoff points to predict benefit from gefitinib in a phase 3 placebo‐controlled study in … FR Hirsch, R Dziadziuszko, N Thatcher, H Mann, C Watkins, DV Parums, ... Cancer: Interdisciplinary International Journal of the American Cancer …, 2008 | 97 | 2008 |
| Long-term (180-day) outcomes in critically ill patients with COVID-19 in the REMAP-CAP randomized clinical trial S Florescu, D Stanciu, M Zaharia, A Kosa, D Codreanu, A Kidwai, ... Jama 329 (1), 39-51, 2023 | 81 | 2023 |
